Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4087 - Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatinib therapy


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  GIST


Hanna Kosela Paterczyk


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


H. Kosela Paterczyk1, A. Paziewska2, M. Kulecka2, J. Karczmarski3, M. Dabrowska3, A. Kluska3, A. Balabas3, M. Piatkowska3, M. Mikula3, P. Rutkowski1, J. Ostrowski2

Author affiliations

  • 1 Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 2 Department Of Gastroenterology, Hepatology And Clinical Oncology, Centre of Postgraduate Medical Education, 02-781 - Warsaw/PL
  • 3 Department Of Genetics, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL


Abstract 4087


Deregulation of microRNAs (miRNAs) expression is observed virtually in all major types of neoplasm and miRNAs level in blood circulation are investigated as a potential diagnostics or prognostics biomarkers for neoplastic disorders. Gastrointestinal stromal tumors (GISTs) is the most common sarcoma of the gastrointestinal tract and to date performed studies on GISTs have provided mounting evidence on altered miRNA association with clinical, pathological features and Imatinib resistance in GIST. However, the utility of circulating miRNA as response markers of GIST progression and for Imatinib treatment have not been evaluated


36 metastatic or unresectable CD-117-positive GIST patients, were enrolled and serum sample was collected prior to Imatinib treatment. All patients responded initially to imatinib therapy. In 12 patients an additional serum sample was collected following targeted treatment at the time of remission. Control group comprised 30 healthy individuals. MiRNAs were isolated from serum with MirVANA miRNA Isolation Kit and then analyzed using deep sequencing on Ion Torrent PGM. Reads were mapped to miRBase miRNA collection with miRDeep2. Differential expression was evaluated with edgeR.


Deep sequencing identified 1284 miRNAs. The pair-wise comparison between Imatinib treated and Imatinib-naive GIST samples uncovered 22 miRNAs with differential expression (adjusted p value


Circulating miRNA abundances can distinguish GIST patients from those in remission following Imatinib therapy as well as from the healthy controls. However, further studies evaluating the potential of designated microRNAs as response markers for treatment or as predictive markers of GIST are warranted.

Clinical trial identification

Legal entity responsible for the study

Piotr Rutkowski


the grant from National Science Center [2013/11/B/NZ5/03165 to PR


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.